Latest in Osteoporosis
Reuters Health • The Doctor's Channel Daily Newscast
‘Timed Up and Go’ test a strong predictor of fracture risk
1:41 | Click to Play
Reuters Health • The Doctor's Channel Daily Newscast
Vitamin D may decrease risk of falls
1:54 | Click to Play
Reuters Health • The Doctor's Channel Daily Newscast
Suicidal ideation twice as common as normal in patients with arthritis
1:48 | Click to Play
Coverage of the American Association of Clinical Endocrinologists 2011 Conference
AACE 2011 Conference – Abstract Highlights – Long Term Effects of Denosumab in Postmenopausal Osteoporosis
1:35 | Click to Play
Reuters Health • The Doctor's Channel Daily Newscast
Glucocorticoid-related bone loss prevented with zoledronate
1:40 | Click to Play
More in Osteoporosis
USPSTF Recommendation
Vitamin D and Calcium Supplements May Not Prevent Fractures in Adults
Feb 26, 2013
| Emergency Medicine, Family Medicine, Internal Medicine, Nephrology, Osteoporosis, Public Health & Prevention, The Daily Dose, Women’s Health
According to a new report in the Annals of Internal Medicine, the USPSTF “concludes that the current evidence is insufficient to assess the balance of the benefits and harms of combined vitamin D and calcium supplementation for the primary prevention of fractures in premenopausal women or in...
Reuters Health • The Doctor's Channel Daily Newscast
Denosumab beneficial through six years in women with low bone mass
Jan 3, 2011
| Endocrinology, Family Medicine, Internal Medicine, Orthopedics, Osteoporosis, Reuters Health • The Doctor's Channel Daily Newscast, Women’s Health
NEW YORK (Reuters Health) – In postmenopausal women with low bone mass, continuous treatment with denosumab — 2 doses per year for up to 6 years — is well tolerated and results in progressive gains in bone mineral density (BMD), results of an extension study indicate.
Denosumab (Prolia, Amgen)...
Reuters Health • The Doctor's Channel Daily Newscast
Denosumab effective for breast cancer-related bone metastases
Nov 12, 2010
| Comprehensive Cancer Collection, Hematology-Oncology, Oncology, Osteoporosis, Reuters Health • The Doctor's Channel Daily Newscast, Women’s Health
NEW YORK (Reuters Health) – Compared with zoledronic acid, the monoclonal antibody denosumab is more effective in delaying skeletal-related events in women with breast cancer that has metastasized to bone, according to the results of a new study.
The finding is reported in the November 8 online issue...
“Asymptomatic” Gaucher Homozygotes
Sep 16, 2010
Chronic Pancreatitis and Fractures
Sep 8, 2010
Lasofoxifene Not Linked To Cancer
Aug 18, 2010
Updated Steroid-Induced Osteoporosis Guidelines
Aug 4, 2010
Efavirenz linked to severe vitamin D deficiency
Jul 8, 2010
Statins don’t prevent fractures: review
May 25, 2010
Teriparatide reduces steroid-induced fractures
Nov 10, 2009
Levothyroxine should be taken in a fasting state
Oct 28, 2009
Anabolic agents that build bone
Aug 14, 2009
Denosumab – a new treatment for osteoporosis
Aug 4, 2009
Infertility and Polycystic Ovarian Syndrome
Jun 18, 2009
